Related Experiment Video

Updated: Feb 10, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

A Global Assessment of Circulating Prolysyl Oxidase in Nonischemic Patients With Garden-variety Heart Failure With

Benjamín Muñoz Calvo1, Ana Villa Martínez1, Susana López Orgil2

  • 1Unidad de Manejo Integral del Paciente con Insuficiencia Cardiaca, Servicio de Medicina Interna, Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain.

Revista Espanola De Cardiologia (English Ed.)
|May 30, 2018
PubMed

Insights

Patients with hypertensive-metabolic heart failure with preserved ejection fraction (HM-HFpEF) have elevated circulating prolysyl oxidase (cpLOX) levels. High cpLOX is linked to poor outcomes and predicts cardiovascular events in HM-HFpEF patients.

Area of Science:

  • Cardiology
  • Biochemistry
  • Heart Failure Research

Background:

  • Lysyl oxidase (LOX) is implicated in myocardial remodeling in hypertensive cardiomyopathy.
  • Hypertensive-metabolic heart failure with preserved ejection fraction (HM-HFpEF) is a growing clinical concern.
  • The role of circulating prolysyl oxidase (cpLOX) in HM-HFpEF remains underexplored.

Purpose of the Study:

  • To investigate elevated cpLOX concentrations in patients with HM-HFpEF.
  • To explore the association of cpLOX with myocardial stiffness and collagen turnover.
  • To determine the prognostic value of cpLOX in HM-HFpEF.

Main Methods:

  • Quantification of cpLOX in 85 HM-HFpEF patients and 51 controls.
  • Assessment of correlations between cpLOX, myocardial stiffness (E/E' ratio, stiffness constants), and fibrogenic markers (BNP, galectin-3).
  • 1-year follow-up using Kaplan-Meier and Cox regression analyses for clinical outcomes.

Main Results:

  • Patients with HM-HFpEF exhibited significantly higher cpLOX levels compared to controls.
  • cpLOX correlated positively with myocardial stiffness parameters.
  • Elevated cpLOX (> 52.20 ng/mL) predicted increased risk of cardiovascular death or hospitalization (HR 1.360).

Conclusions:

  • Symptomatic HM-HFpEF patients present with elevated serum cpLOX, associated with restrictive diastolic filling.
  • cpLOX serves as a moderate risk factor for adverse clinical outcomes in HM-HFpEF.
  • cpLOX levels dynamically correlate with diastolic dysfunction markers, including BNP and galectin-3, during disease progression.
Abstract

Keywords:
B-type natriuretic peptideGalectin-3Galectina-3Heart failure with preserved ejection fractionInsuficiencia cardiaca con fracción de eyección conservadaLisil-oxidasaLysyl oxidasePéptido natriurético cerebral

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
987
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
937
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
385
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
352